Residual β-cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents

Diabetes Care

Volumn 36, Issue 11, 2013, Pages 3454-3459

  Sørensen, Jesper S ^a   Johannesen, Jesper ^b   Pociot, Flemming ^c   Kristensen, Kurt ^a   Thomsen, Jane ^d   Hertel, N Thomas ^e   Kjaersgaard, Per ^f   Brorsson, Caroline ^c   Birkebaek, Niels H ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d KOLDING HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f HERNING HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

AGE DISTRIBUTION; ARTICLE; CELL FUNCTION; CHILD; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; ONSET AGE; PANCREAS ISLET BETA CELL; PRESCHOOL CHILD; PREVALENCE; RISK REDUCTION; ADOLESCENT; DIABETES MELLITUS, TYPE 1; GLUCOSE BLOOD LEVEL; MEAL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REGISTER;

ADOLESCENT; BLOOD GLUCOSE; C-PEPTIDE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MEALS; REGISTRIES;

EID: 84891855250     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0418     Document Type: Article

References (34)

1. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 29. 2010;464:1293-300.
2. Sherry NA, Tsai EB, Herold KC. Natural history of beta-cell function in type 1 diabetes. Diabetes 2005;54(Suppl. 2):S32-S39
3. Tsai EB, SherryNA, Palmer JP,Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 2006;49:261-270
4. Palmer JP. C-peptide in the natural history of type 1 diabetes. DiabetesMetab Res Rev 2009;25:325-328
5. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987;65:30-36
6. Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic b-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010;59: 2846-2853
7. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836
8. Sjöberg S, Gjötterberg M, Berglund L, Möller E, Ostman J. Residual C-peptide excretion is associated with a better long-term glycemic control and slower progress of retinopathy in type I (insulin-dependent) diabetes mellitus. J Diabet Complications 1991;5:18-22
9. Nakanishi K, Kobayashi T, Miyashita H, et al. Relationships among islet cell antibodies, residual beta-cell function, and metabolic control in patients with insulindependent diabetes mellitus of long duration: use of a sensitive C-peptide radioimmunoassay. Metabolism 1990; 39:925-930
10. Nakanishi K,Watanabe C. Rate of beta-cell destruction in type 1 diabetes influences the development of diabetic retinopathy: protective effect of residual beta-cell function for more than 10 years. J Clin Endocrinol Metab 2008;93:4759-4766
11. Panero F, Novelli G, Zucco C, et al. Fasting plasma C-peptide and micro-and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 2009;32:301-305
12. Muhlhauser I, Overmann H, Bender R, Bott U, Berger M. Risk factors of severe hypoglycaemia in adult patientswith Type I diabetesda prospective population based study. Diabetologia 1998;41:1274-1282
13. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998;128:517-523
14. Komulainen J, Knip M, Lounamaa R, et al.; The Childhood Diabetes in Finland Study Group. Poor beta-cell function after the clinical manifestation of type 1 diabetes in children initially positive for islet cell specific autoantibodies. Diabet Med 1997;14:532-537
15. Bonfanti R, Bognetti E, Meschi F, et al. Residual beta-cell function and spontaneous clinical remission in type 1 diabetes mellitus: the role of puberty. Acta Diabetol 1998;35:91-95
16. Böber E, Dundar B, Buyukgebiz A. Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2001;14:435-441
17. Picardi A, Visalli N, Lauria A, et al. Metabolic factors affecting residual beta cell function assessed by C-peptide secretion in patients with newly diagnosed type 1 diabetes. Horm Metab Res 2006;38:668-672
18. Mortensen HB, Swift PGF, Holl RW, et al.; Hvidoere Study Group on Childhood Diabetes. Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes 2010;11:218-226
19. Schiffrin A, Suissa S, Weitzner G, Poussier P, LallaD. Factors predicting course of beta-cell function in IDDM. Diabetes Care 1992;15: 997-1001
20. Egger M, Gschwend S, Smith GD, Zuppinger K. Increasing incidence of hypoglycemic coma in children with IDDM. Diabetes Care 1991;14:1001-1005
21. Fourlanos S, Varney MD, Tait BD, et al. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care 2008;31:1546-1549
22. Gillespie KM, Bain SC, Barnett AH, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 2004; 364:1699-1700.
23. Vendrame F, Zappaterreno A, Dotta F. Markers of beta cell function in type 1 diabetes mellitus. Minerva Med 2004;95: 79-84
24. Daneman D, Clarson C. Residual beta-cell function in children with type 1 diabetes: measurement and impact on glycemic control. Clin Invest Med 1987;10:484-487
25. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264
26. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al.; Type 1Diabetes TrialNet Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971
27. Besser REJ, Shields BM, Casas R, Hattersley AT, Ludvigsson J. Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care 2013;36: 195-201
28. Hoelzel W, Weykamp C, Jeppsson J-O, et al.; IFCC Working Group on HbA1c Standardization. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004;50:166-174
29. Sorensen JS, Vaziri-Sani F, Maziarz M, et al.; Danish Study Group for Childhood Diabetes. Islet autoantibodies and residual beta cell function in type 1 diabetes children followed for 3-6 years. Diabetes Res Clin Pract 2012;96:204-210
30. Nordwall M, Ludvigsson J. Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years. Diabetes Metab Res Rev 2008;24: 472-479
31. Greenbaum CJ, Anderson AM, Dolan LM, et al.; SEARCH Study Group. Preservation of beta-cell function in autoantibodypositive youth with diabetes. Diabetes Care 2009;32:1839-1844
32. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012;35:1436-1445
33. Taborsky GJ Jr, Mundinger TO. Minireview: The role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. Endocrinology 2012;153:1055-1062
34. Sherr J, Tamborlane WV, Xing D, et al.; Diabetes Research in Children Network (DirecNet) Study Group. Achievement of target A1C levels with negligible hypoglycemia and low glucose variability in youth with short-term type 1 diabetes and residual b-cell function. Diabetes Care 2012;35:817-820